EST
SAGE

EA Series Trust’s Sage Therapeutics SAGE Stock Holding History

EA Series Trust’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$2.69M Buy
+57,153
New +$2.84M 0.09% 309

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EA Series Trust's SAGE Position: Q2 2023 in Review

EA Series Trust opened a new position in Sage Therapeutics (SAGE) in Q2 2023: 57,153 shares worth $2.69M. The stake represents 0.09% of the portfolio and ranks #309 among its holdings.

224 funds tracked by Wall St. Rank hold SAGE as of Q2 2023.

  • EA Series Trust held 57,153 shares of Sage Therapeutics worth $2.69M as of Q2 2023.
  • Sage Therapeutics was a new EA Series Trust position in Q2 2023.
  • Sage Therapeutics made up 0.09% of EA Series Trust's portfolio in Q2 2023, its #309 holding.
  • 224 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2023.

Based on EA Series Trust's 13F filing for Q2 2023, filed 27 Jul 2023.